Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned a consensus rating of “Hold” from the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $28.50.
Several equities research analysts have recently weighed in on the company. BidaskClub lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Jefferies Group LLC reissued a “buy” rating and set a $25.00 price objective on shares of CytomX Therapeutics in a research note on Wednesday, April 26th. Zacks Investment Research lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 29th. HC Wainwright reissued a “buy” rating on shares of CytomX Therapeutics in a research note on Monday, May 8th. Finally, ValuEngine lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th.
In related news, insider Sean A. Mccarthy sold 4,481 shares of the stock in a transaction on Monday, June 26th. The stock was sold at an average price of $15.00, for a total transaction of $67,215.00. Following the completion of the sale, the insider now directly owns 8,726 shares in the company, valued at $130,890. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Sean A. Mccarthy sold 4,781 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $15.52, for a total value of $74,201.12. Following the sale, the insider now owns 9,026 shares of the company’s stock, valued at $140,083.52. The disclosure for this sale can be found here. Insiders sold 32,062 shares of company stock valued at $497,641 in the last 90 days. Corporate insiders own 8.00% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Legal & General Group Plc raised its stake in shares of CytomX Therapeutics by 28.6% in the second quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,434 shares in the last quarter. Highbridge Capital Management LLC purchased a new stake in shares of CytomX Therapeutics during the fourth quarter valued at about $158,000. Hillsdale Investment Management Inc. purchased a new stake in shares of CytomX Therapeutics during the first quarter valued at about $159,000. First Quadrant L P CA purchased a new stake in shares of CytomX Therapeutics during the second quarter valued at about $160,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of CytomX Therapeutics during the first quarter valued at about $190,000. Institutional investors and hedge funds own 52.33% of the company’s stock.
CytomX Therapeutics (CTMX) traded up 5.27% during trading on Friday, hitting $14.37. The stock had a trading volume of 130,273 shares. The stock’s market cap is $528.08 million. The firm’s 50-day moving average price is $14.72 and its 200-day moving average price is $14.43. CytomX Therapeutics has a 1-year low of $9.84 and a 1-year high of $20.02.
CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.30. The company had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million. CytomX Therapeutics had a negative return on equity of 59.65% and a negative net margin of 208.92%. On average, equities research analysts predict that CytomX Therapeutics will post ($1.41) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was first posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.themarketsdaily.com/2017/08/08/analysts-set-cytomx-therapeutics-inc-ctmx-price-target-at-28-50.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.